Genetic variation in the glucocorticoid pathway involved in interindividual differences in the glucocorticoid treatment. (February 2017)

• Record Type: Journal Article
• Authors: Song, Qian-Qian; Xie, Wan-Ying; Tang, Yong-Jun; Zhang, Jun; Liu, Jie
• Is Part Of: Pharmacogenomics. Volume 18:Number 3(2017)
• Page Start: 293
• Page End: 316
• Publication Date: 2017-02
• Subjects: glucocorticoid -- glucocorticoid pathway -- glucocorticoid resistance -- pharmacogenetics -- polymorphisms; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0151
• Languages: English
• ISSNs: 1462-2416

Abstract

Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a subgroup of patients, failure to respond to GCs is known as GC resistance or GC insensitivity. This represents an important barrier to effective treatment and a clinical problem requiring an urgent solution. Genetic variation in the GC pathway is a significant factor in interindividual differences in GC treatment. This article reviews the pharmacogenetics of GCs in diverse diseases based on the GC pathway.